Previous studies have focused on the improvements in β-cell function, while the inhibition of α-cell secretion ... On day 1, GLP-1 was infused to stimulate endogenous insulin release and ...
A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.
Boosting Bacteroides vulgatus in diabetic mice increased GLP-1 secretion, improving blood sugar control and reducing sugar cravings.
Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...
Lexaria Bioscience Corp., a global innovator in drug delivery platforms, has announced partial final results showcasing the tolerability and glycemic control efficacy findings from human study ...
Biomea Fusion (BMEA) announced the company will become a diabetes and obesity medicines company. Based on the most recent clinical trial ...
Detailed price information for Lexaria Bioscience Corp WT (LEXXW-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback